subject: Israel's Teva Pharmaceutical Pfizer Beat 5.0 Billion Annexation Ratiopharm-pfizer - [print this page] Teva CEO ShlomaYanai (right) and Ratiopharm parent VEM chairman Hans-JoachimZiems in the March 18 press conference.
3 18, the world's largest Generic Israel's Teva plant Pharmacy Announced, will be 5 billion U.S. dollars to buy German generic manufacturer Ratiopharm large companies, this will enable Teva to further strengthen its generics industry leading position.
Beat Pfizer and Iceland Actavis? A long time, Teva has been the overseas acquisitions as an important development strategy. In 2008, Teva 75 billion acquisition of Barr Pharmaceuticals Inc. of the United States, which is a manufacturer of Contraceptives Generic drug companies. In 2005, Teva acquired with a 7.4 billion U.S. dollars the other competitors, the production of generic drugs in the United States, Ivax Corporation.
Ratiopharm's The sale, however, has attracted industry attention because one of the rival bid is the world's largest Pharmaceutical companies Pfizer, the Icelandic company Actavis generic drug manufacturer is the third bidder.
With the United States and other developed countries Drugs Sell Slower growth year after year, Ratiopharm auction action also highlights the patents behind the company's strategic development of drug production trends: the expansion in the worldwide implementation of the action, they increase more and more generic product portfolio.
JP Morgan, an analyst said on Pfizer, this is the focus of a company's strategic shift; while Teva, it hit a beautiful victory, Teva acquired from the integration of its target will leave a good track record.
Pfizer refused to confirm its participation in the Ratiopharm media auction action, and said, Pfizer will not be on the other to evaluate the company's trading operations.
Ratiopharm trading action, if in accordance with the plan to complete before the end of this year, then it will be on Teva is an important acquisition, because Germany is the world's second largest generic market after the United States.
The European market leader In the March 18 conference call with investors, the CEO of ShlomoYanai Teva, said in the German generic market size of about 88 billion U.S. dollars.
From a broader scale, this acquisition will enable Teva, including the United Kingdom and Spain, including 10 European markets become a leader in the field of generic drugs, and in 17 European markets among the industry the top three.
Yanai said: "This transaction fully in keeping with Teva's long-term development strategy, business development for Europe is an important pillar of growth momentum, Ratiopharm will we in the European market, especially in Germany and generic fast development of markets such as Spain, Italy and France, and enhance Teva's leadership position in providing an ideal platform. With this acquisition, we will become Europe's largest generic drug company. "
Combined income of two companies in 2009 reached 16.2 billion U.S. dollars. Teva North America CEO WilliamMarth said in an interview, as Ratiopharm have a global business, this transaction will greatly enhance Teva's position in Canada, so that Teva holds a market share in Canada close to the local maximum The generic drug manufacturer Apotex Inc.. Teva said it has agreed to 3.625 billion euros acquisition of Ratiopharm. The transaction value includes about 30 billion euros Ratiopharm equity, and about 600 million euros of debt for the payment of Ratiopharm.
